Merck revenue beats estimates on Keytruda demand By Reuters

© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid//File Photo

(Reuters) – Merck & Co Inc reported quarterly revenue on Thursday ahead of analysts’ estimates, as a recovery in demand for its cancer drug Keytruda helped offset a hit to sales of some of the company’s vaccines due to rising COVID-19 cases.

Vaccine demand has taken a hit due to people missing routine inoculations during the pandemic, and government guidelines to avoid other shots in close proximity to getting COVID-19 vaccines.

Sales of Merck’s measles and mumps vaccines ProqQuad was $516 million in the reported quarter, missing estimates of $541 million, according to Refinitiv IBES data. Sales of Pneumovax to prevent pneumococcal pneumonia and other infections caused by similar bacteria was $152 million, compared with estimates of $193.67 million.

The company said in April it was starting to see a recovery in sales of some products, albeit slower than previously expected due to a resurgence of COVID-19 cases.

Sales of Keytruda, the company’s blockbuster cancer therapy, rose 23% to $4.2 billion in the reported quarter, in line with estimates of $4.21 billion, according to nine analysts polled by Refinitiv.

The company has said delayed cancer diagnoses during the pandemic contributed to less patients starting treatment with the therapy.

Merck, however, has continued to gain expanded approvals for Keytruda’s use, putting it on track to become the world’s best selling drug by 2023, according to research firm GlobalData.

The company’s second-quarter sales rose 22% to $11.40 billion, beating estimates of $11.10 billion.

Quarterly profit nearly halved as Merck took a $1.7 billion charge due to its acquisition of Pandion and expenses related to drug development.

On an adjusted basis, the company earned $1.31 per share, in line with analysts’ estimates.

Merck’s shares fell 2% to $76.76 in premarket trading.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*